New Portal Hypertension Research from Nara Medical University Outlined (Tofogliflozin Delays Portal Hypertension and Hepatic Fibrosis by Inhibiting Sinusoidal Capillarization in Cirrhotic Rats).

Předmět:	HEPATIC fibrosis PORTAL hypertension DIGESTIVE system diseases RATS
Zdroj:	Cardiovascular Week; 4/8/2024, p545-545, 1p
Abstrakt:	A recent study conducted by researchers at Nara Medical University in Japan has found that the drug tofogliflozin may delay the progression of portal hypertension (PH) and hepatic fibrosis in rats with liver cirrhosis. Portal hypertension is a condition that occurs as a result of liver cirrhosis and is characterized by the capillarization of liver sinusoidal endothelial cells (LSECs). Tofogliflozin, an antidiabetic agent, was found to prevent PH and liver fibrosis in the rat model by reducing vasoconstriction and sinusoidal capillarization. The drug also suppressed inflammation and fibrogenesis in the liver. These findings suggest that tofogliflozin may be a potential treatment option for liver cirrhosis-related PH. [Extracted from the article]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu